IQ EQ FUND MANAGEMENT IRELAND Ltd Has $8.79 Million Stock Position in Medtronic PLC $MDT

IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in shares of Medtronic PLC (NYSE:MDT) by 7.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,269 shares of the medical technology company’s stock after purchasing an additional 6,400 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Medtronic were worth $8,788,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Riverbend Wealth Management LLC raised its position in Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after purchasing an additional 107 shares in the last quarter. Wynn Capital LLC grew its position in Medtronic by 2.4% in the third quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after acquiring an additional 110 shares during the last quarter. Meridian Investment Counsel Inc. lifted its holdings in shares of Medtronic by 0.4% in the third quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after acquiring an additional 110 shares during the last quarter. Saxony Capital Management LLC boosted its stake in shares of Medtronic by 3.8% in the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares in the last quarter. Finally, Cape Investment Advisory Inc. grew its holdings in shares of Medtronic by 3.2% during the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after purchasing an additional 113 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Daiwa Capital Markets increased their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. UBS Group reiterated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a report on Wednesday. Stifel Nicolaus raised their price objective on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a report on Thursday, October 9th. TD Cowen restated a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Morgan Stanley increased their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Fifteen analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.67.

Medtronic Stock Up 1.1%

Shares of MDT opened at $102.92 on Friday. The stock’s 50-day moving average price is $99.44 and its two-hundred day moving average price is $96.01. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33. The company has a market capitalization of $131.95 billion, a PE ratio of 27.74, a PEG ratio of 2.68 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.8%. Medtronic’s payout ratio is 76.55%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Analysts remain constructive — several outlets highlight bullish analyst views on Medtronic, supporting confidence in longer‑term growth prospects. Analysts Are Bullish on These Healthcare Stocks: Medtronic (MDT)
• Positive Sentiment: Product/market expansion — coverage notes Medtronic is broadening its heart and diabetes tools and integrating new offerings, which can support revenue growth and investors’ valuation assumptions. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Positive Sentiment: Strategic M&A — Medtronic expanded its cath lab portfolio with the CathWorks acquisition, strengthening structural/cath lab offerings and cross‑sell opportunities. That helps offset competitive pressure in some device categories. Medtronic expands cath lab portfolio with CathWorks acquisition
• Neutral Sentiment: New analyst coverage — Citigroup began coverage of MDT, which can increase analyst attention and trading liquidity; the ultimate impact depends on the published rating and target. Citigroup Begins Coverage on Medtronic (NYSE:MDT)
• Neutral Sentiment: Valuation and investor commentary are mixed — several pieces debate whether recent gains leave MDT reasonably priced; these discussions can moderate momentum but don’t directly change fundamentals. Is Medtronic (MDT) Still Reasonably Priced After Recent Share Price Gains?
• Neutral Sentiment: Leadership change — the president of Structural Heart, Nina Goodheart, is retiring; this is notable for execution risk in that business but not an immediate financial shock. Medtronic Structural Heart President Nina Goodheart to retire
• Neutral Sentiment: Market performance context — one note shows MDT outperformed intraday but underperformed peers on the day, signaling relative-strength questions even amid gains. Medtronic PLC stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: Major legal setback — a U.S. jury found Medtronic unlawfully monopolized the market for certain vessel‑sealing devices and ordered roughly $382 million in damages to Applied Medical; this is the most immediate negative catalyst and creates financial, reputational and potentially precedent risks. Medtronic owes $382 million to medical device rival in antitrust lawsuit, US jury says Applied Medical Prevails in Antitrust Jury Trial Against Medtronic

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).